For instance, patients with squamous cell lung cancer and FGFR1 amplification demonstrate significantly reduced overall survival (OS) compared to those without amplification (58.6 months vs. 80.0 months) [17]. This evidence concerns the gene FGFR1 and squamous cell lung carcinoma.